Pharmaceutical - Cardio-vascular, Oncology


Current filters:


Popular Filters

1 to 25 of 37 results

Added indications recommended by EMA/CHMP

Added indications recommended by EMA/CHMP


Along with backing for approval for six news drugs issued at the late June meeting of the European Medicines…

AvastinBayerBristol-Myers SquibbCardio-vascularEliquisEuropeEyleaKalydecoOncologyOphthalmicsPfizerPharmaceuticalRare diseasesRegulationRocheVertex Pharmaceuticals

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline


Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review


US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Catalyst-rich period ahead for key trial results from BioLineRx


Israeli drug developer BioLineRx is entering a catalyst-rich phase over the next 12 months, which will…


EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox


At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates


The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Radiopharmaceuticals market to hit a value of $7.9 billion by 2018


The radiopharmaceuticals market has been forecast to exceed a value of $7.9 billion by 2018, driven by…

Cardio-vascularGlobalMarkets & MarketingNeurologicalOncologyPharmaceutical

Increased breast cancer risk with long-term use of calcium-channel blockers for hypertension


Long-term use of a calcium-channel blocker to treat hypertension (high blood pressure) is associated…


Developing cancer cures is top priority for Americans, survey shows


A new survey commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) shows 86%…

Cardio-vascularHealthcareNorth AmericaOncologyPharmaceuticalResearch

India's NPPA to slash prices of key drugs by up to half


In India, some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis…


Abcam in deal with Pfizer to supply compounds to researchers


UK-based Abcam (AIM: ABC), a producer and distributor of protein research tools, has entered into a license…


Negative late-stage trial results for Sanofi's iniparib and otamixaban


There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…


Amgen and Astellas link up on drugs for unmet medical needs in Japan


World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

SOBI gains distribution rights for Megace, Monopril, Cefzil and Duricef from PharmaSwiss


Swedish Orphan Biovitrum (STO: SOBI) says that it has entered into a distribution agreement with privately-held…

Antibiotics and Infectious diseasesCardio-vascularCefzilDuricefEuropeLicensingMegaceMonoprilOncologyPharmaceuticalPharmaSwissSobiSwedish Orphan Biovitrum

Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis


In final guidance published (January 23, 2013), UK drugs watchdog the National Institute for Health and…

Bristol-Myers SquibbCardio-vascularEliquisEuropeJavlorOncologyPfizerPharmaceuticalPierre FabrePricingRegulation

Bayer initiates Ph III trail of Xarelto in cardiac event prevention; R&D day presentation


German drug major Bayer (BAYN: DE) has initiated the Phase III COMPASS study of its oral anticoagulant…


News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments


US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

1 to 25 of 37 results

Back to top